Arena Pharmaceuticals Inc

Arena Pharmaceuticals — Investor Presentation (February 2018)

27 slides from Arena Pharmaceuticals's investor presentation, Feb 15, 2018

  1. Slide 1: Corporate Presentation February 2018

    Slide 1: Corporate Presentation February 2018

    February 2018 Non-Confidential Corporate Presentation Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-class), safety, effic

  3. Slide 3: Executive Summary: Catalyst Rich 2018

    Slide 3: Executive Summary: Catalyst Rich 2018

    Executive Summary Catalyst Rich 2018 - Multiple Potentially First / Best-in-Class Programs Q1 Q2 2H Ralinepag Ph 3 program plan Etrasimod UC Ph 2 data APD371 Crohn’s pain Ph 2 data Ralinepag Ph 3 initiation Etrasimod new indications initiation Cardiopulmonary pipeline expansion Etrasimod in PBC & PG

  4. Slide 4: Focus on Pipeline: Differentiated Assets with High-Value Potential

    Slide 4: Focus on Pipeline: Differentiated Assets with High-Value Potential

    Program Therapeutic Area/Indication PC Ph 1 Ph 2 Ph 3 Timing Ralinepag Potent IP Receptor Agonist Pulmonary Arterial Hypertension (PAH) Ph 3 Preparations Etrasimod Optimized Activity S1P Receptor Modulator Ulcerative Colitis (UC) Ph 2 Data Q1 2018 Primary Biliary Cholangitis (PBC) Initiated Ph 2 Pyo

  5. Slide 5: Ralinepag

    Slide 5: Ralinepag

    A Next-Generation, Oral, Selective Prostacyclin Receptor (IP) Agonist for the Treatment of Pulmonary Arterial Hypertension Ralinepag

  6. Slide 6: Phase 3 Ready Ralinepag: Potential to Redefine Treatment Paradigm in PAH

    Slide 6: Phase 3 Ready Ralinepag: Potential to Redefine Treatment Paradigm in PAH

    Phase 3 Ready Ralinepag 1996 Barst - Unremitting 24 h coverage with IV prostacyclin improves survival1 Difficulty of administration and maintenance limits IV to last line Unmet Need in $6.7B2 PAH Market 6.5-10x improved potency compared to selexipag Long half-life (>24 h), IV-like unremitting recept

  7. Slide 7: Ralinepag Significantly Improved Pulmonary Vascular Resistance

    Slide 7: Ralinepag Significantly Improved Pulmonary Vascular Resistance

    Ralinepag Significantly Improved Pulmonary Vascular Resistance (PVR); ITT Population Primary Endpoint: Change in PVR Geometric Mean Ratio (GMR) [Expressed as Percent Change] Treatment Effect Comparison -25.8% over placebo (p=0.02) Mean absolute change from baseline: placebo 25.5, ralinepag -175.7 dy

  8. Slide 8: Safety and Tolerability

    Slide 8: Safety and Tolerability

    The overall safety and tolerability profile consistent with the known profile of the prostacyclin therapy class Adverse events that occurred most frequently on ralinepag were similar to the on-target effects expected for prostacyclin therapies: Headache, nausea, diarrhea, jaw pain, flushing Events w

  9. Slide 9: Ralinepag Phase 3 Clinical Program: Three Studies Initiating in Parallel

    Slide 9: Ralinepag Phase 3 Clinical Program: Three Studies Initiating in Parallel

    Ralinepag Phase 3 Clinical Program Three Studies Initiating in Parallel Ph 3 Studies 1 – Exercise Capacity Registrational 2 - Comparator / Head-to-Head Supportive 3 – Clinical Events Label Expansion Endpoints 1º-CPET 2º -6MWD Hemodynamics Time to clinical events Incident or Prevalent Incident Confid

  10. Slide 10: CPET Provides a Multi-Dimensional Assessment of Exercise Capacity

    Slide 10: CPET Provides a Multi-Dimensional Assessment of Exercise Capacity

    CPET Provides a Multi-Dimensional Assessment of Exercise Capacity More Accurate Measurement of Exercise Capacity Peak VO2 (maximum oxygen consumed during exercise) VE/VCO2 (minute ventilation / carbon dioxide production) Key CPET Measures Highly sensitive measure of impact - both diagnostic and prog

  11. Slide 11: VE/VCO2 Slope and Other CPET Variables in Guideline-Based PAH Management

    Slide 11: VE/VCO2 Slope and Other CPET Variables in Guideline-Based PAH Management

    6MWD <165m 6MWD 165-440m Intermediate Risk (5-10% estimated 1y mortality) 6MWD >440m Adapted from Galiè, N et al European Heart Journal (2016) 37, 67–119 doi:10.1093/eurheartj/ehv317 VE/VCO2 Slope and Other CPET Variables are Integral Components of Guideline-Based PAH Management High Risk (>10% esti

  12. Slide 12: CPET Superior Measurement for Exercise Capacity

    Slide 12: CPET Superior Measurement for Exercise Capacity

    CPET Superior Measurement for Exercise Capacity Less subjective Lower variability Minimizes confounding factors Course design BMI Co-morbid conditions i.e. scleroderma Weather Greater sensitivity to detect treatment effect 1) Arena R et al. Circulation. 2007 May 8;115(18):2410-7. doi: 10.1161/CIRCUL

  13. Slide 13: Etrasimod

    Slide 13: Etrasimod

    Oral, Next Generation, S1P Receptor Modulator Optimized Activity Being Evaluated for Multiple Immune-Inflammatory Diseases Etrasimod

  14. Slide 14: Promise of Etrasimod

    Slide 14: Promise of Etrasimod

    Promise of Etrasimod Unmet need for safe and effective oral agents addressing a broad range of immune-inflammatory diseases S1P modulation offers the promise of effective treatment in 80+ conditions First-generation pan-S1P modulators (fingolimod - Gilenya®) risk-benefit profile limits utility Secon

  15. Slide 15: Etrasimod's Highly Selective S1P Modulation May Avoid Off-Target Activity

    Slide 15: Etrasimod's Highly Selective S1P Modulation May Avoid Off-Target Activity

    Associated with Cardiac, Pulmonary & Possible Tumor-related Risks Decreased Inflammation & Improvement in Immune-Inflammatory Disorders Positive Outcome Negative Outcome Dendritic Cells Reduces Immune Cell Migration, Differentiation & Proliferation Increased Vasoconstriction, Fibrosis & Proliferatio

  16. Slide 16: Etrasimod Does Not Induce S1PR2 Internalization

    Slide 16: Etrasimod Does Not Induce S1PR2 Internalization

    In Contrast with Other S1P Modulators, Etrasimod Does Not Induce S1PR2 Internalization (In Vitro Studies) S1P Agonists Induce S1PR1 Internalization (S1PR1 Internalization Assay) Etrasimod Does Not Induce S1PR2 Internalization (S1PR2 Internalization Assay) -12 -11 -10 -9 -8 -7 -6 -5 log [Agonist] (M)

  17. Slide 17: Optimal Selectivity: Opportunity to be Best-in-Class

    Slide 17: Optimal Selectivity: Opportunity to be Best-in-Class

    Optimal Selectivity Opportunity to be best-in-class therapy More Selective S1P2 internalization Ozanimod2 (Celgene) Nonselective Promiscuous binding can lead to off-target effects4 & more AEs5 a Elevated LFTs ≥ 3 × upper limit of normal. *Note – Data Collected from Separate Studies – Cannot be Direc

  18. Slide 18: Etrasimod Has a Quick Onset of Action

    Slide 18: Etrasimod Has a Quick Onset of Action

    Etrasimod Has a Quick Onset of Action – Phase 1 Data *After dose escalation of ozanimod (0.3 mg/d on days 1–3; 0.6 mg/d on days 4 and 5; 1 mg/d on days 6 and 7; and 3 mg/d on days 8–10. Data truncated at day 11 (ozanimod) and 15 (etrasimod) to show on-treatment onset effects Sources: 1-Tran JQ et al

  19. Slide 19: Etrasimod Has a Quick Offset of Action

    Slide 19: Etrasimod Has a Quick Offset of Action

    Etrasimod Has a Quick Offset of Action – Phase 1 Data Sources: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-996. 2- ADP334 P1 Data on File; Ozanimod1 Etrasimod2 Ozanimod, 1 mg (Fixed dose) Placebo Etrasimod, 2 mg (Fixed Dose) Placebo Treatment days Within 1 week after last dose of etrasimod, lymph

  20. Slide 20: Etrasimod First Dose Has Little Impact on Heart Rate

    Slide 20: Etrasimod First Dose Has Little Impact on Heart Rate

    Etrasimod First Dose Has Little Impact on Heart Rate Over 24 Hrs – Phase 1 Data Ozanimod, 1 mg Single Dose (n=18) Ozanimod, 2 mg Single Dose (n=12) Placebo (n=9) Etrasimod, 2 mg, Single Dose (n=10) Ozanimod1 Etrasimod2 Note – Data Collected from Separate Studies – Cannot be Directly Compared Sources

  21. Slide 21: Etrasimod Phase 2 Trial in UC

    Slide 21: Etrasimod Phase 2 Trial in UC

    Enrolled patients with moderate to severe UC (3-component Mayo score of 4-9 that includes endoscopic sub score >2, rectal bleeding score >1) Efficacy endpoints include improvement in Mayo Clinical Score (3-component, total), response, remission, mucosal healing versus placebo and dose response Safet

  22. Slide 22: Etrasimod Clinical Program: Expanding Indications

    Slide 22: Etrasimod Clinical Program: Expanding Indications

    Etrasimod Clinical Program Expanding Indications 1. Vavricka, SR et al. ”Extraintestinal Manifestations of Inflammatory Bowel Disease” Inflammatory Bowel Diseases August 2015 2. Taverela VF. ”Review article: skin complications associated with inflammatory bowel disease” Aliment Pharmacol Ther 2004 3

  23. Slide 23: APD371

    Slide 23: APD371

    APD371 Peripherally Restricted, Highly–Selective, Full Agonist to Cannabinoid 2 Receptor (CB2) Being Evaluated for Treatment of Pain Associated with Crohn’s Disease

  24. Slide 24: Promise of APD371

    Slide 24: Promise of APD371

    Promise of APD371 Opioid epidemic is a public health emergency No drugs developed for the treatment of visceral pain including: Inflammatory bowel disease Interstitial cystitis Pancreatitis Endometriosis Chronic prostatitis 1/8 IBD patients on chronic opioids Unmet Need in Pain Designed to be periph

  25. Slide 25: CB2 Receptors Are Expressed in the Enteric Nervous System and Immune Cells

    Slide 25: CB2 Receptors Are Expressed in the Enteric Nervous System and Immune Cells

    CB2 Receptors Are Expressed in the Enteric Nervous System and Immune Cells Within GI Tract CB2 receptors located in target tissue, neurons & local immune cells in GI tract CB2 receptor also expressed on visceral afferent nerves During inflammation, enhanced expression on epithelial cells at the ulce

  26. Slide 26: Executive Summary: Catalyst Rich 2018

    Slide 26: Executive Summary: Catalyst Rich 2018

    Executive Summary Catalyst Rich 2018 - Multiple Potentially First / Best in Class Programs Q1 Q2 2H Ralinepag Ph 3 program plan APD371 Crohn’s pain Ph 2 data Ralinepag Ph 3 initiation Etrasimod new indications initiation Cardiopulmonary pipeline expansion Etrasimod in PBC & PG Next Up – Etrasimod Ph

  27. Slide 27: Thank you

    Slide 27: Thank you

    PHARMACEUTICALS Thank you NASDAQ: ARNA

Source: SEC EDGAR · 8-K filed Feb 15, 2018

More decks from Arena Pharmaceuticals Inc